EGFR and non-small cell lung carcinoma: AB-329 (formerly DS-1205b), a selective small-molecule AXL inhibitor, has demonstrated safety and preliminary efficacy in combination with EGFR inhibitors in clinical trials for non-small cell lung cancer (NSCLC) [15,16].